Neumora Therapeutics Files 8-K/A Amendment
Ticker: NMRA · Form: 8-K/A · Filed: Apr 11, 2025 · CIK: 1885522
| Field | Detail |
|---|---|
| Company | Neumora Therapeutics, INC. (NMRA) |
| Form Type | 8-K/A |
| Filed Date | Apr 11, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, amendment
Related Tickers: NMRA
TL;DR
Neumora amended its 8-K to update director elections and exec pay details.
AI Summary
Neumora Therapeutics, Inc. filed an 8-K/A on April 11, 2025, to amend a previous filing regarding changes in its board of directors and executive compensation. Specifically, the amendment addresses the election of new directors and updates information related to compensatory arrangements for certain officers, effective February 13, 2025.
Why It Matters
This filing provides updated information on Neumora's corporate governance and executive compensation structure, which can be important for investors assessing the company's leadership and financial strategy.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, primarily updating corporate governance and compensation information, which typically carries a low risk.
Key Numbers
- 001-41802 — SEC File Number (Identifies the company's filing history with the SEC.)
- 84-4367680 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Neumora Therapeutics, Inc. (company) — Registrant
- February 13, 2025 (date) — Effective date of changes
- April 11, 2025 (date) — Filing date of amendment
- Delaware (location) — State of incorporation
- Watertown, Massachusetts (location) — Principal executive offices
FAQ
What specific changes are being amended in this 8-K/A filing?
The filing amends previous information regarding the election of directors and updates details on compensatory arrangements for certain officers.
What is the effective date of the changes reported in this amendment?
The earliest event reported is effective as of February 13, 2025.
When was this 8-K/A amendment filed with the SEC?
The amendment was filed on April 11, 2025.
What is Neumora Therapeutics, Inc.'s state of incorporation?
Neumora Therapeutics, Inc. is incorporated in Delaware.
What is the company's principal executive office address?
The principal executive offices are located at 490 Arsenal Way, Suite 200, Watertown, Massachusetts 02472.
Filing Details
This Form 8-K/A (Form 8-K/A) was filed with the SEC on April 11, 2025 regarding Neumora Therapeutics, Inc. (NMRA).